Palavras-chave
controle de qualidade
prazo de validade
potência
estabilidade
Como Citar
Resumo
As vacinas contra a hepatite B são produzidas pela expressão do gene viral codificado para o antígeno de superfície do vírus da hepatite B (HBsAg) em levedura, há mais de 20 anos. De acordo com os dados da OMS, a vacina de hepatite B tem até três anos de estabilidade quando armazenada entre 2 ºC e 8 ºC. O objetivo deste estudo foi de avaliar se, no momento da liberação, os critérios de qualidade da vacina de hepatite B foram mantidos após sete anos da data de validade. Foram analisados frascos de vacinas multi-dose (10 e 5 doses), sendo três lotes de cada produtor (A, B e C). Todos os lotes foram avaliados quanto às características de aparência visual, potência, endotoxina bacteriana, presença de timerosal, conteúdo de hidróxido de alumínio e pH por meio de testes validados. Os nove lotes avaliados sete anos após a data de expiração tiveram resultados similares quando comparados às concentrações na época de liberação dos lotes, realizada pelo Instituto Nacional de Controle de Qualidade em Saúde (INCQS). Os estudos confirmaram a manutenção da qualidade da vacina após o período de expiração. Estes dados podem subsidiar uma futura avaliação para extensão do prazo de validade das vacinas.
Referências
1. Seeger C, Zoulim F, Mason WS. Hepadnaviruses. In: Fields Virology. 6ª ed. Knipe DM, Howley PM (eds). Lippincott Williams & Wilkins, PA, USA, 2013. 2185-221.
2. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine.2008;26:6266-73. [DOI: 10.1016/j.vaccine.2008.09.056].
3. World Health Organization -WHO. Immunization, Vaccines and Biologicals. Hepatitis B. Geneva; 2010.
4. World Health Organization -WHO. Immunization, Vaccines and Biologicals. Hepatitis B. Geneva; 2014. [acesso 2014 Nov 20]. Disponível em: [http://www.who.int/immunization/diseases/hepatitisB/en/].
5. Decker MD. Principles of pediatric combination vaccines and practical issues related to use in clinical practice. Pediatr Infect Dis J.2001;20(11 Suppl):S10-8.
6. Decker M, Bogaerts H, Edwards K. Combination vaccines. In: Plotkin S, Orenstein W, Offit PA (eds).Vaccines. 5a ed. USA: Saunders Co; 2008. p. 1069-101.
7. Ellis RW. Development of combination vaccines. Vaccine.1999;17(13-14):1635-42. [DOI: 10.1016/S0264-410X(98)00424-1].
8. Pichichero ME. New combination vaccines. Pediatr Clin North Am.2000;47(2):407-26. [DOI: 10.1016/S0031-3955(05)70214-5].
9. World Health Organization - WHO. Requirements for Hepatitis B vaccines Made Recombinant DNA Techniques. In: WHO Expert Committee on Biological Standardization. Thirty–ninth report. Geneva, 1989, Annex 2, WHO Technical Report Series n. 786.
10. World Health Organization -WHO. Requirements for Hepatitis B vaccines Made Recombinant DNA Techniques. In: WHO Expert Committee on Biological Standardization. Forty–eighth report. Geneva, 1999, Annex 4, WHO Technical Report Series n. 889. p. 94-95. [acesso 2014 Out 20]. Disponível em: [http://apps.who.int/iris/bitstream/10665/42202/1/WHO_TRS_889.pdf ].
11. European Pharmacopoeia. Hepatitis B vaccine, 8.0, volume I, 01/2014. Strasbourg: EDQM Council of Europe.
12. U.S. Food and Drug Administration - FDA. Biological Products: general provisions. Code of Federal Regulations. Title 21, sec 600.15 -Temperatures during shipment. Washington, DC: US Government Printing Office; 2007.
13. European Directorate for the Quality of Medicines & Health Care – EDQM. EU Administrative procedure for Official Control Authority batch release: Control authority batch release of vaccines and blood products. Strasbourg: Council of Europe, 2012.
14. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância das Doenças Transmissíveis. Nota Técnica Conjunta n.2/2013/CGPNI/DEVEP e CGDHRV/DST-AIDS/SVS/MS. Ampliação da oferta da vacina hepatite B para a faixa etária de 30 a 49 anos em 2013. Brasília: Ministério da Saúde, 2013. [acesso 2015 Jun 11]. Disponível em: [http://www.saude.rs.gov.br/upload/1372685606_11%20Nota%20Tecnica%20N%C2%BA%20022013%20-%20vacina%20hepatite%20B%2030%20a%2049%20anos.pdf].
15. US Centers for Disease Control and Prevention - CDC. Update expanded availability of thimerosal preservative – free hepatitis B vaccine. Morb Mort Weekly Rep.2000;49(28):642-65.
16. Clapp T, Siebert P, Chen D, Braun LTJ. Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability. J Pharm Sci.2011;100(2):388-401. [DOI: 10.1002/jps.22284].
17. United States Pharmacopeia – USP 23 - National Formulary 19. Rockville: The United States Pharmacopeial Convention; 2000.
18. Birner J, Garnet JR. Thimerosal as a preservative in biological preparations. I. Application of polarography to the determination of thimerosal in aqueous solutions and vaccines. J Pharm Sci.1964 Oct; 53:1264-5.
19. Page JE, Waller JG. Polarographic determination of thiomersalate. Analyst.1949;74:292-6. [DOI: 10.1039/AN9497400292].
20. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). ICH Harmonised Tripartite Guideline. ICH Q1A (R2): Stability Testing of New Drug Substances and Products. February 6, 2003. [acesso 2014 Out 24]. Disponível em: [http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1A_R2/Step4/Q1A_R2__Guideline.pdf].
21. U.S. Food and Drug Administration - FDA. Biological Products: general provisions. Code of federal regulations. Title 21, sec 600.3. Washington, DC: US Government Printing Office; 2007.
22. World Health Organization – WHO, Global Programme for Vaccines and Immunization. Thermostability of vaccines. Geneva: WHO; 1998. (Publication WHO/GPV/98.07)
23. Dobbelaer R. Collaborative study for the establishment of biological reference preparations for rDNA hepatitis B vaccine. Pharmeuropa Special Issue, BIO 1997; 2:3-18.
24. European Pharmacopeia. Method of analysis, Biological assays. Assay of hepatitis B vaccine (rDNA). General chapter 2.7.15. 5ª ed. Strasbourg, France: Council of Europe; 2005.
25. European Pharmacopeia. Statistical analysis, 8.0, volume I, 01/2014. Strasbourg: EDQM Council of Europe.
26. European Pharmacopeia. Bacterial Endotoxins, 7.0. Strasbourg: Council of Europe, 2011; p.171-5.
27. Farmacopeia Brasileira. 4 ed., parte 2, n. 5, São Paulo: Atheneu, 2004.
28. Birner J, Garnet JR. Thimerosal as a preservation in biological preparations. Application of polarography to the determination of thimerosal in aqueous solutions and vaccines. J Pharm Sci.1964;53(10):1263-5.
29. Baylor NW, Egan W, Richman P. Aluminum salts in vaccines – US perspective. Vaccine.2002;20(Suppl 3):S18-23.
30. Gupta RK. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev.1998;32(3):155-172.
31. Finney DJ. Chapter 4 Parallel line assays. In: Statistical Methods in Biological Assay. 3ª ed. London: Charles Griffin and Company Ltd; 1978. p. 69-104.
32. Hendriksen CFM, Garthoff B, Aggerbeck H, Bruckner L, Castle P, Cussler K et al. Alternatives to animal testing in the quality control of immunobiologicals: current status and future prospects. The report and recommendations of ECVAM workshop 4. ATLA.1994; 22:420-34.
33. Pierard I, Spelte G, Le Tallec D, Duchêne M. Consideration on a few aspects of the stability studies post licensure. Biologicals.2009;37(6):403-6. [DOI: 10.1016/j.biologicals.2009.08.011].
34. Fairweather WR, Mogg R, Bennett PS, Zhong J, Morrisey C, Schofield TL. Monitoring the stability of human vaccines. J Biopharm Stat.2003;13(3):395-413. [DOI:10.1081/BIP-120022762].
35. Schofield TL. Maintenance of vaccine stability through annual stability and comparability studies. Biologicals.2009;37(6):397-402.[DOI: 10.1016/j.biologicals.2009.08.010].
36. World Health Organization - WHO. Recommendations to Assure the Quality, Safety and Efficacy of Recombinant Hepatitis B Vaccines. Proposed replacement of: WHO Technical Report Series, Nº 786, Annex 2 and Technical Report Series, Nº 889, Annex 4. Geneva, World Health Organization, 2010. [acesso 2014 Nov 06]. Disponível em: [http://www.who.int/biologicals/HEP_B_Recomm_after_ECBS_endorsment_final].
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Copyright (c) 2016 Renata Faria de Carvalho, Simone Ferreira Teixeira Bastos, Fernando Fingola, Kátia Christina Leandro, Catia Ines Costa